Takeda reports MM data for MLN9708

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said once-weekly 4 mg oral MLN9708 plus Revlimid lenalidomide and dexamethasone met the primary endpoint in the Phase II portion of an open-label, dose-escalation Phase I/II trial to treat previously untreated multiple myeloma (MM). In 52 evaluable patients, 35% of patients had a very good partial response and 23% had a complete response. Very good partial responses were defined as a 90% or greater reduction in abnormal myeloma proteins in the blood. Data were presented at the American Society of Hematology meeting in Atlanta. MLN9708 is an orally available proteasome inhibitor.

Takeda expects data from the Phase III TOURMALINE-MM1 trial of MLN9708 in MM no earlier than late 2014. In October, Takeda's Millennium Pharmaceuticals Inc. subsidiary started the Phase III TOURMALINE-AL1 trial of MLN9708 to treat relapsed or refractory systemic light chain amyloidosis. The product is an orally available proteasome inhibitor. ...